The effect of adjuvant chemotherapy in patients with intrahepatic cholangiocarcinoma: a matched pair analysis

被引:32
|
作者
Schweitzer, Nora [1 ]
Weber, Tim [1 ]
Kirstein, Martha M. [1 ]
Fischer, Mareike [1 ,2 ]
Kratzel, Anna-Maria [1 ]
Reineke-Plaass, Tanja [3 ]
Lehner, Frank [4 ]
Manns, Michael P. [1 ]
Vogel, Arndt [1 ]
机构
[1] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Carl Neuberg Str 1, D-30625 Hannover, Germany
[2] Klinikum Hildesheim, Dept Cardiol Angiol & Intens Care, Senator Braun Allee 33, D-31135 Hildesheim, Germany
[3] Hannover Med Sch, Dept Pathol, Carl Neuberg Str 1, D-30625 Hannover, Germany
[4] Hannover Med Sch, Dept Gen Visceral & Transplantat Surg, Carl Neuberg Str 1, D-30625 Hannover, Germany
关键词
Cholangiocarcinoma; CCA; Intrahepatic; ICC; Survival; Adjuvant chemotherapy; PROGNOSTIC-FACTORS; SURGICAL-TREATMENT; MORTALITY-RATES; UNITED-STATES; TRENDS; SURVIVAL; BILIARY; EXPERIENCE; INCREASE; CANCER;
D O I
10.1007/s00432-017-2392-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The purpose of this study was to identify prognostic factors of patients with intrahepatic cholangiocarcinoma (ICC) treated with resection and to investigate the effect of adjuvant chemotherapy (CT). Patients with ICC diagnosed between 2000 and 2015 treated at Hannover Medical School were included. Clinicopathologic characteristics were analyzed in univariate and multivariate analysis. In a matched pair survival analysis, patients with or without adjuvant CT were matched by these prognostic factors. Two hundred and ten patients were included. Median survival was 28.7 months, 1-, 3-, and 5-year survival rates were 72.8%, 29.6%, and 14.1%, respectively. In multivariate analysis, lymph node involvement (p = 0.006, HR 1.84), larger tumor size (p = 0.013, HR 1.79), vascular invasion (p = 0.038, HR 1.70), and prolongation of prothrombin time (p < 0.001, HR 4.20) were significantly related to poor survival. Thirty-nine patients received adjuvant CT of which 60% had lymph node involvement. Each 25 patients with and without adjuvant CT were matched to the identified prognostic factors. The median survival of patients with adjuvant CT was 33.5 months, compared to 18 months in the control group (p = 0.002). The 1-, 3-, and 5-year survival rates were 96, 36, and 12%, compared to 60, 4, and 0% in non-treated patients. We identified several prognostic factors for patients with ICC treated with resection. Our data support the use of adjuvant CT in patients with ICC. The results of prospective randomized controlled studies will clarify the role of adjuvant CT in the future.
引用
收藏
页码:1347 / 1355
页数:9
相关论文
共 50 条
  • [11] The influence of resection margin width in patients with intrahepatic cholangiocarcinoma: a meta-analysis
    Dai, Yu-Shi
    Hu, Hai-Jie
    Lv, Tian-run
    Hu, Ya-Fei
    Zou, Rui-Qi
    Li, Fu-Yu
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2023, 21 (01)
  • [12] Synergy of Losartan and chemotherapy for patients with cholangiocarcinoma: A propensity score-matched analysis
    Li, Qing
    Chang, Zhenyu
    Wang, Tianyi
    Liu, Bing
    Wang, Ximin
    Ge, Xin-Yu
    Yang, Tao
    Liu, Qu
    Wang, Wei
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [13] The effect of preoperative chemotherapy treatment in surgically treated intrahepatic cholangiocarcinoma patients-A multi-institutional analysis
    Buettner, Stefan
    Koerkamp, Bas Groot
    Ejaz, Aslam
    Buisman, Florian E.
    Kim, Yuhree
    Margonis, Georgios Antonios
    Alexandrescu, Sorin
    Marques, Hugo P.
    Lamelas, Jorge
    Aldrighetti, Luca
    Gamblin, T. Clark
    Maithel, Shishir K.
    Pulitano, Carlo
    Bauer, Todd W.
    Shen, Feng
    Poultsides, George A.
    Marsh, J. Wallis
    IJzermans, Jan N. M.
    Pawlik, Timothy M.
    JOURNAL OF SURGICAL ONCOLOGY, 2017, 115 (03) : 312 - 318
  • [14] Postoperative adjuvant transarterial chemoembolization for intrahepatic cholangiocarcinoma patients with microvascular invasion: a propensity score analysis
    Cheng, Zhangjun
    Lei, Zhengqing
    Jin, Xiaoling
    Zhang, Qi
    Si, Anfeng
    Yang, Pinghua
    Zhou, Jiahua
    Hartmann, Daniel
    Huser, Norbert
    Shen, Feng
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2021, 12 (02) : 819 - +
  • [15] Adjuvant chemotherapy in resectable cholangiocarcinoma patients
    Wirasorn, Kosin
    Ngamprasertchai, Thundon
    Khuntikeo, Narong
    Pakkhem, Ake
    Ungarereevittaya, Piti
    Chindaprasirt, Jarin
    Sookprasert, Aumkhae
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 (12) : 1885 - 1891
  • [16] Liver transplantation for intrahepatic cholangiocarcinoma: a propensity score-matched analysis
    Huang, Gaobo
    Song, Weilun
    Zhang, Yanchao
    Yu, Jiawei
    Lv, Yi
    Liu, Kang
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [17] Chemotherapy for Surgically Resected Intrahepatic Cholangiocarcinoma
    Miura, John T.
    Johnston, Fabian M.
    Tsai, Susan
    George, Ben
    Thomas, Jim
    Eastwood, Dan
    Banerjee, Anjishnu
    Christians, Kathleen K.
    Turaga, Kiran K.
    Pawlik, Timothy M.
    Gamblin, T. Clark
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (11) : 3716 - 3723
  • [18] Adjuvant Therapy for Intrahepatic Cholangiocarcinoma: The Debate Continues
    Zhu, Andrew X.
    Knox, Jennifer J.
    ONCOLOGIST, 2012, 17 (12) : 1504 - 1507
  • [19] Outcomes of adjuvant treatments for resectable intrahepatic cholangiocarcinoma: Chemotherapy alone, sequential chemoradiotherapy, or concurrent chemoradiotherapy
    Lin, Yen-Kuang
    Hsieh, Mao-Chih
    Wang, Wei-Wei
    Lin, Yi-Chun
    Chang, Wei-Wen
    Chang, Chia-Lun
    Cheng, Yun-Feng
    Wu, Szu-Yuan
    RADIOTHERAPY AND ONCOLOGY, 2018, 128 (03) : 575 - 583
  • [20] Systemic and Adjuvant Therapies for Intrahepatic Cholangiocarcinoma
    Chun, Yun Shin
    Javle, Milind
    CANCER CONTROL, 2017, 24 (03)